Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

B. Riley Securities Maintains Buy on WideOpenWest, Lowers Price Target to $19

By Benzinga Newsdesk

October 14, 8:12 AM

B. Riley Securities analyst Daniel Day maintains WideOpenWest (NYSE:WOW) with a Buy and lowers the price target from $25 to $19.

WOW

Analyst Ratings

Analyst Ratings for Duke Energy

By Benzinga Insights

January 4, 5:00 PM

Within the last quarter, Duke Energy (NYSE:DUK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

DUK

Predictive Oncology Announces Collaboration With Integra Therapeutics To Advance Gene Therapy

By Happy Mohamed

March 30, 8:44 AM

Predictive Oncology (NASDAQ:POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on

POAI

Casino Gaming Operator Melco Resorts & Entertainment Misses On Q3 Despite Y/Y Recovery

By Shivani Kumaresan

November 7, 1:44 PM

Melco Resorts & Entertainment Ltd (NASDAQ: MLCO) reported third-quarter FY23 sales growth of 321% year-on-year to $1.017 billion,

MLCO

JP Morgan Downgrades Cyteir Therapeutics to Neutral

Related Posts

B. Riley Securities Maintains Buy on WideOpenWest, Lowers Price Target to $19

Analyst Ratings for Duke Energy

Predictive Oncology Announces Collaboration With Integra Therapeutics To Advance Gene Therapy

Casino Gaming Operator Melco Resorts & Entertainment Misses On Q3 Despite Y/Y Recovery